GlassScriptPhysician profile
Jane T Chew
NPI 1114986429
$18,311.58
in general payments reported to CMS, 2019-2025
37 companies · $3,678 in 2025
The $3,678 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,087 · 2020: $1,429 · 2021: $1,680 · 2022: $2,177 · 2023: $2,596 · 2024: $3,666 · 2025: $3,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,689 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,689.47 |
| Education | $250.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,314.81 | 2019-2025 | Dupixent |
| Abbvie INC. | $1,879.36 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Leo Pharma INC. | $1,572.68 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $1,155.97 | 2019-2025 | |
| Janssen Biotech, INC. | $1,047.53 | 2019-2025 | Tremfya |
| Ucb, INC. | $957.45 | 2019-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $884.13 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $860.95 | 2021-2025 | Opzelura, Opzelura |
| Novartis Pharmaceuticals Corporation | $800.18 | 2019-2025 | |
| Journey Medical Corporation | $699.04 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $625.01 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Genzyme Corporation | $586.92 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $537.97 | 2019-2023 | Arazlo |
| Lilly USA, LLC | $505.32 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Almirall LLC | $457.30 | 2019-2025 | Klisyri |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $438.27 | 2020-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $381.46 | 2022-2024 | Sotyktu |
| Epi Health, LLC | $377.55 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $363.46 | 2020-2021 | |
| Dermavant Sciences, INC. | $330.26 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $320.26 | 2023-2025 | Zoryve |
| Organon LLC | $258.71 | 2024-2025 | Vtama |
| Encore Dermatology INC. | $122.74 | 2019 | |
| Mayne Pharma Commercial LLC | $110.78 | 2019-2020 | |
| Botanix Sb INC | $106.37 | 2025 | Sofdra |
| Celgene Corporation | $100.23 | 2019 | |
| Dermira, INC. | $96.16 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.82 | 2024-2025 | Spevigo |
| Takeda Pharmaceuticals U.S.A., INC. | $77.26 | 2025 | |
| Prugen, INC. Pharmaceuticals | $61.33 | 2019 | |
| Hill Dermaceuticals, INC. | $46.55 | 2024 | Tolak |
| Aclaris Therapeutics, INC. | $40.07 | 2019 | |
| Sebela Pharmaceuticals INC. | $27.22 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $22.14 | 2024 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $19.84 | 2021 | |
| Krystal Biotech INC | $16.58 | 2025 | Vyjuvek |
| Mission Pharmacal Company | $15.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Chew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.